Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER: Real World Clinical Outcomes With ETI in Cystic Fibrosis
NCT04602468Phase 4Active, not recruiting
- Sponsor
- Royal College of Surgeons of England
- Start
- Sep 2020
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Royal College of Surgeons of England. Primary endpoint: Lung Clearance Index at 84 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04602468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602468.